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Abstract: CD25
High CD4
+ regulatory T cells (Treg cells)
have been described as key players in immune regulation,
preventing infection-induced immune pathology and
limiting collateral tissue damage caused by vigorous
anti-parasite immune response. In this review, we
summarize data obtained by the investigation of Treg
cells in different clinical forms of Chagas’ disease. Ex vivo
immunophenotyping of whole blood, as well as after
stimulation with Trypanosoma cruzi antigens, demonstrat-
ed that individuals in the indeterminate (IND) clinical form
of the disease have a higher frequency of Treg cells,
suggesting that an expansion of those cells could be
beneficial, possibly by limiting strong cytotoxic activity
and tissue damage. Additional analysis demonstrated an
activated status of Treg cells based on low expression of
CD62L and high expression of CD40L, CD69, and CD54 by
cells from all chagasic patients after T. cruzi antigenic
stimulation. Moreover, there was an increase in the
frequency of the population of Foxp3
+ CD25
HighCD4
+
cells that was also IL-10
+ in the IND group, whereas in the
cardiac (CARD) group, there was an increase in the
percentage of Foxp3
+ CD25
High CD4
+ cells that expressed
CTLA-4. These data suggest that IL-10 produced by Treg
cells is effective in controlling disease development in IND
patients. However, in CARD patients, the same regulatory
mechanism, mediated by IL-10 and CTLA-4 expression is
unlikely to be sufficient to control the progression of the
disease. These data suggest that Treg cells may play an
important role in controlling the immune response in
Chagas’ disease and the balance between regulatory and
effector T cells may be important for the progression and
development of the disease. Additional detailed analysis
of the mechanisms on how these cells are activated and
exert their function will certainly give insights for the
rational design of procedure to achieve the appropriate
balance between protection and pathology during
parasite infections.
Introduction
A substantial number of studies have been published on the
analysis of the human immune response against the infection by
the protozoa Trypanosoma cruzi. Those studies have evaluated the
putative role of various cell populations, their subsets and
cytokines, and their correlation with the regulation of the immune
response during T. cruzi infection [1–13].
Regulatory T cells (Treg cells) have been described as a unique
population of CD25
+ CD4
+ T cells, a class of cells that regulates
innate and adaptive immune responses and has the capacity to
control the excessive or misdirected effect of the immune response,
including those to pathogens or self-antigens [14–19]. In infectious
diseases caused by protozoan parasites, a number of publications
have focused on the role of Treg cells in patients with Chagas’
disease [9,10,13,20,21].
Thepurposeofthisreviewistohighlighttheprogressoverthepast
few years in the investigation of Treg cells in different clinical forms
of Chagas’ disease. Although new data on the regulatory
mechanisms that control diseases continue to accumulate, there is
stillsignificantneedforfurtheranalysisofthevariouscellpopulations
in T. cruzi infection that will allow testing of new hypotheses to
elucidate the mechanisms that lead to the development of the
different clinical forms of the disease as well as the mechanisms of
protection. It is important to mention that the papers cited in this
article were selected based on some criteria such as stringency of the
papers in relation to the subjects discussed, high quality of papers,
and papers indexed in the PubMed database (Box 1).
Regulatory T Cells in Chagas’ Disease
Chagas’ disease, or American trypanosomiasis, is a severe
infection caused by the haemoflagellate protozoa T. cruzi.I ti sa
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approximately 8 million people in South and Central America
[22]. In humans, T. cruzi infection usually develops from an
oligosymptomatic acute phase to a possibly debilitating chronic
phase that can manifest itself in a variety of ways. The majority of
patients who progress to the chronic phase remain clinically
asymptomatic for many years, with no clinical, radiological, or
electrocardiographic manifestations of cardiac or digestive in-
volvement. These conditions characterize the indeterminate
clinical form of the disease [23]. Between 30% and 40% of the
infected individuals progress to the cardiac (CARD) and/or
digestive (DIG) symptomatic disease. It is estimated that 30% of all
infected individuals will eventually develop heart disease [23–25].
The specific mechanisms associated with the establishment/
maintenance of the distinct clinical outcomes of Chagas’ disease
are undoubtedly extremely complex. Understanding why only a
percentage of the infected individuals develop severe manifesta-
tions of the disease and why the clinical forms are highly
heterogeneous is of major importance not only for the compre-
hension of the immune mechanisms and clinical forms but, most
importantly, for the implementation of adequate therapies and
care for these individuals. Several studies have demonstrated that
different clinical forms are associated with distinct and complex
host–parasite relationships directly involving the immune response
[1,3,26–34]. In fact, it is well accepted that the absence of chagasic
pathology is mainly associated with an individual’s ability to
regulate the anti–T. cruzi immune response, which controls
persistent parasitism but can also contribute to the inflammatory
collateral damage that causes Chagas’ disease morbidity.
Our group has, for several years, studied the role of the immune
response in the development of the different clinical forms of
Chagas’ disease. The initial cohort of study subjects was recruited
8 years ago at the Outpatient Referral Center for Chagas Disease
of the Hospital das Clı ´nicas, Federal University of Minas Gerais,
Brazil. All study participants provided a written informed consent
Box 1. Methods
The papers cited in this article were selected based on the
following criteria: 1) Stringency of the papers in relation to
the subjects discussed. 2) High quality of papers. 3) Papers
indexed in the PubMed database.
Box 2. Key Learning Points
N Regulatory T cells have been described as a unique
population of CD25
+ CD4
+ T cells that regulates innate
and adaptive immune responses and has the capacity to
control the excessive or misdirected effect of the
immune response.
N Regulatory T cells through expression of IL-10 are
beneficial to patients in the indeterminate clinical form
by maintaining a balance between efficient effector cells
that kill the parasites and avoiding the development of
tissue immunopathology.
N CD25
HighCD4
+ T cells use different mechanisms to
regulate the immune response during Chagas’ disease
and the host-parasite interactions may be influenced by
the ratio of regulatory/effectors T cells.
N The generation of protection or pathogenic responses in
human Chagas’ disease is highly influenced by the
suggested balance of the complex immune response
induced by T. cruzi.
N Indeterminate patients have an effective, and possibly
transitory, control of the response to the infection
mediated by regulatory T cells and effectors cells.
Figure 1. Analysis of IL-10
+ CD25
High CD4
+ regulatory T cells in the peripheral blood from chagasic patients. Frequency of regulatory T
cells and intracytoplasmic IL-10 (cIL-10) levels in CD25
High CD4
+ cells from patients with distinct clinical forms of Chagas’ disease (IND, light gray box;
CARD, dark gray box) and non-infected individuals (NI, white box) following short-term in vitro stimulation of whole blood samples with T. cruzi
antigens. Baseline levels of CD25
High CD4
+ and cIL-10
+ T cells were obtained from control cultures (CC) maintained under the same conditions (22 h
incubation at 37uC, CO2 humidified incubator). The results are expressed in box plot format for CD25
High CD4
+ (left panels) and cIL-10
+ T cells (right
panels). The box stretches from the lower hinge (defined as the 25
th percentile) to the upper hinge (the 75
th percentile) and, therefore, contains the
middle half of the score in the distribution. The median is shown as a line across the box. Therefore, 1:4 of the distribution is between this line and the
bottom or the top of the box. Significant differences are identified by connecting lines for comparisons between CC and Ag, and highlighted the
ability of T. cruzi antigens to trigger enhanced levels of CD25
High CD4
+ and cIL-10
+ T cells in both IND and CARD groups. Significant differences
between clinical groups are identified by asterisks as compared to NI.
doi:10.1371/journal.pntd.0000992.g001
www.plosntds.org 2 May 2011 | Volume 5 | Issue 5 | e992following the guidelines of the Ethics Committee of the Federal
University of Minas Gerais. The study protocol complied with the
regulations of the Brazilian National Council on Research in
Humans and was approved by the Ethics Committees of the
Federal University of Minas Gerais under protocol COEP/
UFMG-372/04 and the Ethics Committees of the Oswaldo Cruz
Foundation under protocol CEP-CPqRR 27/2008.
More recently, we have evaluated the potential role of
CD25
High CD4
+ T cells in the control of Chagas’ disease
pathogenesis [9,10,13,20,21]. Our previous evaluation of Treg
cells throughout the expression of the transcription factor Foxp3 in
digestive clinical forms of Chagas’ disease showed an increased
concentration of Foxp3 T cells in IND group without megacolon
compared with those patients with megacolon and non-infected
individuals, suggesting that these cells possibly have an important
role in the intestinal infection and may represent a mechanism
used by patients presenting Chagas’ disease to prevent exacerba-
tion of the inflammation and, consequently, avoid megacolon
development [21] (Box 2).
Ex vivo data obtained from patients with indeterminate and
cardiac clinical forms of Chagas’ disease have shown that there is
an increased frequency of CD25
High CD4
+ Treg cells in the
peripheral blood of IND patients when compared to CARD and
non-infected individuals [9], suggesting that an expansion of
CD25
High CD4
+ Treg cells may be beneficial during the chronic
phase of the disease, probably by limiting tissue damage, leading to
Figure 2. Phenotypic analysis of CD25
High CD4
+ regulatory T cells in the peripheral blood from chagasic patients. Phenotypic features
of CD25
High CD4
+ cells from patients with distinct clinical forms of Chagas’ disease (IND, light gray box; CARD, dark gray box) and non-infected
individuals (NI, white box) following short-term in vitro stimulation of whole blood samples with T. cruzi antigens. Baseline levels for a range of
phenotypic features of CD25
High CD4
+ cells were obtained from control cultures (CC) maintained under the same conditions (22 h incubation at 37uC,
CO2 humidified incubator). The results are expressed in box plot format as the percentage of positive cells within CD25
High CD4
+ cells including those
expressing adhesion molecules CD62L (D) and CD54 (B), co-stimulatory receptors CD40L (A) and CTLA-4 (E), activation marker CD69 (C) and
regulatory receptor IL-10R (F). The box stretches from the lower hinge (defined as the 25
th percentile) to the upper hinge (the 75
th percentile) and,
therefore, contains the middle half of the score in the distribution. The median is shown as a line across the box. Therefore, 1:4 of the distribution is
between this line and the bottom or the top of the box. Significant differences are identified by connecting lines for comparisons between CC and
Ag, and highlighted that T. cruzi antigens triggered an overall change in the phenotypic features of CD25
High CD4
+ cells towards lower frequency of
CD62L
+ and IL-10R
+ cells besides increased levels of CD54
+, CD40L
+, and CD69
+ cells in both IND and CARD groups. Although T. cruzi antigens were
able to induce higher levels of CTLA-4 in both groups of chagasic patients (IND and CARD), the impact of T. cruzi antigens was more pronounced in
CARD, leading to higher frequency of CTLA-4
+ cells in comparison to NI. Adapted from [20].
doi:10.1371/journal.pntd.0000992.g002
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disease. A similar correlation between an increased expansion of
this cell population in the peripheral blood and disease progression
was previously described for non-progressor, asymptomatic-HIV
infected individuals [35].
It has been previously described that regulatory T cells can
suppress the immune response by producing anti-inflammatory
cytokines, such as IL-10 and TGF-b [36]. In an attempt to better
characterize these cells in Chagas’ disease, we investigated whether
CD25
High CD4
+ Treg in the peripheral blood of chagasic patients
are IL-10 producers [20]. We observed an increased frequency of
cytoplasmic (c) IL-10
+ CD25
High CD4
+ Treg cells in both IND
and CARD individuals after in vitro recall responses induced by
exposure to T. cruzi antigens (Figure 1). It is interesting to note that
our group and others have already described an association
between the secretion of IL-10 and the control of immunopathol-
ogy [3,4,9,34,37–39], contrasting with the observed increase in IL-
10
+ CD25
High CD4
+ Treg cells in CARD. However, it is
important to mention that the number of positive cells for this
cytokine is higher in IND individuals (unpublished data). The
differences mentioned may be explained by increasing evidence
that supports the hypothesis that the fine balance of inflammatory
and regulatory cytokines derived from distinct T cell sources is the
key factor for the resulting immune-mediated mechanisms that
drive the disease outcome [3]. In order to confirm if CD25
High
CD4
+ T cells are correlated with improved cardiac function and,
thus, a possible protective role in Chagas’ disease, we performed a
correlation analysis between the frequency of these cells and two
clinical parameters of cardiac function: left ventricular ejection
fraction (LVEF) and left ventricular diastolic diameter (LVDD).
These distinct clinical parameters are directly and inversely
correlated with better cardiac function, respectively. A significant
positive correlation was seen between higher LVEF and higher
frequency of CD25
High CD4
+ T cells and a significant negative
correlation was seen between lower LVDD and higher frequency
of CD25
High CD4
+ T cells. These data suggest that CD25
High
CD4
+ T cells display an import immunoregulatory role that leads
to maintenance of better cardiac function in IND patients
(unpublished data).
Recent data demonstrated that CD4
+ T cells are the major cell
population defining the regulatory profile in IND, whereas
monocytes and CD4
+ T cells determine the inflammatory cytokine
pattern in CARD individuals. Interestingly, in vitro stimulation
with T. cruzi antigen was able to reverse the cytokine balance in
IND and CARD groups [11]. In addition to differential immune
response, other factors are likely to influence the differential
progression of individuals into distinct clinical forms of Chagas’
disease, including parasite strain, the size of inoculation,
environmental factors, and host genetics, among others [40–43].
With the objective of better illustrating the differences in this T
cell population, we have further characterized the CD25
High
CD4
+ Treg cells after in vitro exposure of whole blood to T. cruzi
antigens. As a result, it was observed that CD25
High CD4
+ Treg
cells of chagasic patients express a number of cell surface markers
that have been associated with activation and migration. Human
CD25
High CD4
+ Treg cells from IND and CARD patients
presented an increased expression of CD40L, CD54, and CD69
(Figure 2A, B, and C, respectively) and a decreased expression of
CD62L (Figure 2D) in the peripheral blood. Baecher-Allan and
colleagues [15] first suggested that the CD25
High CD4
+ T cells
may exist in a semi-activated state in vivo, expressing a number of
surface antigens that are usually associated with activated T cells.
Thus, Treg cells may be primed for an anamnestic response upon
re-encountering the parasite antigens. Previous reports have
shown increased levels of adhesion molecules (CD54 and LFA-1)
on regulatory cell subsets [14,44–46], suggesting that these cells
are able to penetrate into inflamed tissues and may act directly at
the sites of inflamation [16,47–49]. Our results are in agreement
with these findings and we suggest that in Chagas’ disease
CD25
High CD4
+ T cells can migrate to the tissues and control the
Figure 3. Analysis of Foxp3
+ CD25
High CD4
+ regulatory T cells in the peripheral blood from chagasic patients. Representative dot plots
illustrate that the increased levels of regulatory T cells observed in T. cruzi antigens-stimulated cultures from IND tend to be higher than that
observed in CARD, and also reflect an increased level of Foxp3
+ CD25
+ cells in the IND group (bottom graphs). Quadrant statistics were used for data
analysis, and the results are expressed as the percentage of positive cells within the CD25
+ CD4
+ selected lymphocytes. Reproduced and adapted
from [20].
doi:10.1371/journal.pntd.0000992.g003
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form of the disease. Additional analyses are currently being
undertaken by our group to further support this hypothesis.
In addition to the above shown cell surface markers, we
evaluated the expression of Foxp3 by these cells. This marker has
been shown to play a key role in Treg cell function and still
represents a highly specific marker for these cells [50–54].
Previously published studies have consistently reported that Foxp3
is predominantly expressed by both human and murine CD25
High
CD4
+ Treg cells. In agreement with previous data, increased levels
of Foxp3+ CD25+ cells were also observed in the IND group after
in vitro stimulation with T. cruzi antigens (Figure 3) [20],
emphasizing once again the role of Treg cells in the control of
Chagas’ disease morbidity.
Regulatory T cells are known to express CTLA-4 constitutively;
however, the role played by this inhibitory signaling molecule in
Treg cells homeostasis and in the regulation of the immune
responses is not yet well defined. CTLA-4 expression has been
associated with Treg cells production of immunosuppressive
cytokines, such as TGF- b and IL-10, and is essential for cell-
contact suppression in vitro [55,56]. We observed a higher
frequency of CTLA-4
+ CD25
High CD4
+ T cells in whole blood
form CARD after in vitro stimulation with T. cruzi antigen, when
compared with non-infected individuals (Figure 2E) [20]. In-
creased numbers of cIL-10
+ cells (Figure 1) were observed in the
CD25
High CD4
+ T lymphocytes from both groups of chagasic
patients (IND and CARD), suggesting that stimulation with T.
cruzi antigens induces secretion of this cytokine by cells from
individuals with the polar clinical forms of the disease. Preliminary
data from our group show that while there is a positive correlation
between cIL-10
+ and CTLA-4
+ cells in IND (spearman indexes
r=0.5985; p=0.0008), the same was not observed in CARD
(spearman indexes r=0.3696; p=0.0652).
An interesting study by Souza et al. 2007 [38] has shown that
the expression of CTLA-4 in T cells from indeterminate patients
was up-regulated; however, the expression of this molecule was not
seen on the surface of cells from cardiac patients. Importantly, the
same group observed higher frequency of IL-10 in IND patients
after in vitro stimulation with T. cruzi antigens. The binding of
CTLA-4 with anti–CTLA-4 mAbs or CD80 ligand was shown to
inhibit IL-2 production and proliferation of primary CD4 T cells
[57,58] and IL-4 and IFN-gamma production of T-cell clones
Figure 4. Proposed hypothesis for CD25
High CD4
+ Treg cells function on immunoregulation in chronic Chagas’ disease. Several
leukocyte subsets have been shown to play a role in immunoregulation during chronic infections. In this model, Chagas’ disease patients with the
indeterminate clinical form show Treg cells able to modulate the effectors’ function of CD8
+ T cells, in a microenvironment supported by cytotoxic
NK-cells, Monocytes and CD4
+ T cells producing regulatory cytokines (IL-10 and IL-10, IL-4, respectively). This immunological milieu contributes to
controlling the parasitemia and regulating the immunopathology. On the other hand, Chagas’ disease patients with cardiac and digestive clinical
forms display insufficient modulation by Treg cells with activated CD8
+ T cells besides monocytes and CD4+ T cells producing inflammatory cytokines
(TNF-a and IFN-c, respectively). This microenvironment triggers immunopathological events and leads to tissue damage in the absence of regulatory
mechanisms and cytotoxic NK-cell functions.
doi:10.1371/journal.pntd.0000992.g004
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binding is able to increase IL-10 and TGF-b, showing an
additional effect in regulating this pathway [60,61]. Therefore,
CTLA-4 may exert its immunoregulatory role through a
bidirectional signaling between CTLA-4 on T cells and B7 on
APCs that result in attenuation of ongoing immune response and
maintenance of T-cell homeostasis. CTLA-4 also acted indirectly
through the development of regulatory T cells producing IL-10
[62], and the suppressive activity may require cell-cell contact and
implies binding with CTLA-4 [55,56]. Thus, the identification if
the contact cell-cell through CTLA-4 to Treg cells produces IL-10
is crucial to understanding their role in Chagas’ disease. These
findings further support our hypothesis that the determining factor
is a balance between cytokines and cell populations in these
individuals. Additional analyses are currently being undertaken to
further support this hypothesis.
Other studies have shown that IL-10 is an important cytokine
involved in the suppressive function of Treg/Tr1 cells [36,63].
Although there is no clear evidence for the effector function of this
cell population in Chagas’ disease, we observed a high percentage
of CD25
High CD4
+ T cells from cardiac patients expressing
CTLA-4, as well as an increase in the frequency of CD25
High
CD4
+ T cells expressing IL-10 (Figure 1) with a simultaneous
decrease in the frequency of IL-10 receptor in IND and CARD
(Figure 2F). Therefore, it is possible that CD25
High CD4
+ Treg
cells from IND patients may be important in controlling type 1
response to T. cruzi. Thus, a hypothesis to be further tested is that
Treg cells, through expression of cIL-10, are beneficial to patients
in the indeterminate clinical form by maintaining a balance
between efficient effector cells that kill the parasites and avoiding
the development of tissue immunopathology. On the other hand,
in CARD patients, these cells are not sufficient and/or competent
to control the inflammatory process mediated by high levels of
activated CD8
+ HLA-DR
+ T cells as previously observed in the
peripheral blood [10] and the inflammatory infiltrate of cardiac
lesions [1,64]. Thus, it is likely that CD25
High CD4
+ T cells use
different mechanisms to regulate the immune response during
Chagas’ disease and that the host-parasite interactions may be
influenced by the ratio of regulatory/effectors T cells. Based on
our observations, the model presented in Figure 4 may explain the
putative mechanisms involved in the control and induction of
pathology in Chagas’ disease and is being used by our group as the
test model of our hypotheses. We argue that the generation of
protection or pathogenic responses in Chagas’ disease is highly
influenced by the suggested balance of this complex immune
response induced by T. cruzi as previously shown by our group and
others. Therefore, cardiac patients have specific cell populations
involved in the establishment of an inflammatory cytokine profile
and lack of control of the immune response. On the other hand,
indeterminate patients have an effective, and possibly transitory,
control of the response to the infection mediated by regulatory and
effector T cells.
Moreover, we hypothesize that a higher cytotoxic activity of NK
cell subsets in IND patients could be important in helping to
suppress parasitemia to very low levels, resulting in avoidance of
the development of a strong acquired immune response against
parasite-specific antigens and the outcome of severe chagasic
disease [65]. The ability to build up NK-mediated cell cytotoxicity
seems to play a pivotal role in the generation of effective,
nondeleterious inflammatory mechanisms. Considering the com-
plexity of the human immune response, this insight suggests that
other immunoregulatory mechanisms come into play to control
the intense immune activity and are apparently necessary to
prevent a deleterious effect of the excessive stimulation of the
immune system, represented by CD25
High CD4
+ Treg cells.
Moreover, the ability of these cells to inhibit IFN-gamma synthesis
confirms previous observations of low levels of IFN-gamma
production by mononuclear cells from patients presenting with
the asymptomatic chronic phase of Chagas’ disease. In addition,
the production of IL-10 by macrophages/monocytes comprises a
supplementary regulatory mechanism to modulate the immune
response in IND patients [3].
Concluding Remarks
This review summarizes the most relevant results regarding the
role of regulatory T cells in Chagas’ disease. Although the
available data do not cover all the gaps and did not address several
questions regarding the mechanisms underlying the recruitment,
activation, and function of regulatory T cells in development of
tissue damage in Chagas’ disease patients, they give important
insights to clearly emphasize that Treg cells are relevant to
modulate the immune response in chronic human T. cruzi
infection (Box 3). Given the complex nature of the immune
response in humans and the low availability of biological samples,
the establishment of such protocols represents an important
drawback in the human studies. Although the interpretation,
suggestions, and conclusions presented here are based on
phenotypic data (not on functional studies), they represent
important advances toward the better understanding of the role
that Treg cells may have in vivo in the different clinical forms of
Chagas’ disease. Moreover, it is important to highlight that while
working with human diseases, it is difficult to perform a large
number of functional studies, since functional analysis using
human Treg cells requires a considerable amount of biological
samples, in contrast with those facilities found when working with
syngeneic experimental models.
Once the relevant phenotypic features of Treg cells associated
with distinct clinical forms of the disease are established, functional
studies might be performed in pre-clinical investigations using in
Box 3. Key Papers in the Field
de Arau ´jo FF, da Silveira AB, Correa-Oliveira R, Chaves AT,
Adad SJ, et al. (2011) Characterization of the presence of
Foxp3(+) T cells from patients with different clinical forms
of Chagas’ disease. Hum Pathol 42(2): 299–301.
Mariano FS, Gutierrez FR, Pavanelli WR, Milanezi CM,
Cavassani KA, et al. (2008) The involvement of CD4
+CD25
+
T cells in the acute phase of Trypanosoma cruzi infection.
Microbes Infect 10(7): 825–833.
Araujo FF, Gomes JA, Rocha MO, Williams-Blangero S,
Pinheiro VM, et al. (2007) Potential role of CD4
+CD25
HIGH
regulatory T cells in morbidity in Chagas disease. Front
Biosci 1(12): 2797–2806.
Vitelli-Avelar DM, Sathler-Avelar R, Massara RL, Borges JD,
Lage PS, et al. (2006) Are increased frequency of
macrophage-like and natural killer (NK) cells, together
with high levels of NKT and CD4+CD25high T cells
balancing activated CD8+ T cells, the key to control
Chagas’ disease morbidity? Clin Exp Immunol 145(1): 81–
92.
Vitelli-Avelar DM, Sathler-Avelar R, Dias JC, Pascoal VP,
Teixeira-Carvalho A, et al. (2005) Chagasic patients with
indeterminate clinical form of the disease have high
frequencies of circulating CD3+CD16-CD56+ natural killer
T cells and CD4+CD25High regulatory T lymphocytes.
Scand J Immunol 62(3): 297–308.
www.plosntds.org 6 May 2011 | Volume 5 | Issue 5 | e992vitro or humanized experimental models. Understanding the
mechanisms by which Treg cells are recruited and activated in
Chagas’ disease patients will contribute to the design of rational
cell therapy approaches to balance protection/pathology and
control clinical morbidity during the chronic disease onset.
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